The protective effect of intranasal immunization with influenza virus recombinant adenovirus vaccine on mucosal and systemic immune response
Copyright © 2024 Elsevier B.V. All rights reserved..
Influenza virus is a kind of virus that poses several hazards of animal and human health. Therefore, it is important to develop an effective vaccine to prevent influenza. To this end we successfully packaged recombinant adenovirus rAd-NP-M2e-GFP expressing multiple copies of influenza virus conserved antigens NP and M2e and packaged empty vector adenovirus rAd-GFP. The effect of rAd-NP-M2e-GFP on the activation of dendritic cell (DC) in vitro and in vivo was detected by intranasal immunization. The results showed that rAd-NP-M2e-GFP promoted the activation of DC in vitro and in vivo. After the primary immunization and booster immunization of mice through the nasal immune way, the results showed that rAd-NP-M2e-GFP induced enhanced local mucosal-specific T cell responses, increased the content of SIgA in broncho alveolar lavage fluids (BALF) and triggered the differentiation of B cells in the germinal center. It is proved that rAd-NP-M2e-GFP can significantly elicit mucosal immunity and systemic immune response. In addition, rAd-NP-M2e-GFP could effectively protect mice after H1N1 influenza virus challenge. To lay the foundation and provide reference for further development of influenza virus mucosal vaccine in the future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:130 |
|---|---|
| Enthalten in: |
International immunopharmacology - 130(2024) vom: 30. März, Seite 111710 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lian, Yi-Bing [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adenovirus Vaccines |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 25.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.intimp.2024.111710 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36884871X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36884871X | ||
| 003 | DE-627 | ||
| 005 | 20240325234938.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.intimp.2024.111710 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1346.xml |
| 035 | |a (DE-627)NLM36884871X | ||
| 035 | |a (NLM)38394888 | ||
| 035 | |a (PII)S1567-5769(24)00228-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lian, Yi-Bing |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The protective effect of intranasal immunization with influenza virus recombinant adenovirus vaccine on mucosal and systemic immune response |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 25.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
| 520 | |a Influenza virus is a kind of virus that poses several hazards of animal and human health. Therefore, it is important to develop an effective vaccine to prevent influenza. To this end we successfully packaged recombinant adenovirus rAd-NP-M2e-GFP expressing multiple copies of influenza virus conserved antigens NP and M2e and packaged empty vector adenovirus rAd-GFP. The effect of rAd-NP-M2e-GFP on the activation of dendritic cell (DC) in vitro and in vivo was detected by intranasal immunization. The results showed that rAd-NP-M2e-GFP promoted the activation of DC in vitro and in vivo. After the primary immunization and booster immunization of mice through the nasal immune way, the results showed that rAd-NP-M2e-GFP induced enhanced local mucosal-specific T cell responses, increased the content of SIgA in broncho alveolar lavage fluids (BALF) and triggered the differentiation of B cells in the germinal center. It is proved that rAd-NP-M2e-GFP can significantly elicit mucosal immunity and systemic immune response. In addition, rAd-NP-M2e-GFP could effectively protect mice after H1N1 influenza virus challenge. To lay the foundation and provide reference for further development of influenza virus mucosal vaccine in the future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Dendritic cells | |
| 650 | 4 | |a Influenza virus | |
| 650 | 4 | |a Mucosal immunity | |
| 650 | 4 | |a NP-M2e antigen | |
| 650 | 4 | |a Recombinant adenovirus vaccine | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 650 | 7 | |a Adenovirus Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Synthetic |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Hu, Man-Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Tian-Kui |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yong-Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Rong-Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Jing-Shu |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Ling-Jiao |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Chun-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Gui-Lian |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Hai-Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Yan-Long |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jian-Zhong |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Wen-Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chun-Feng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International immunopharmacology |d 2001 |g 130(2024) vom: 30. März, Seite 111710 |w (DE-627)NLM112639542 |x 1878-1705 |7 nnns |
| 773 | 1 | 8 | |g volume:130 |g year:2024 |g day:30 |g month:03 |g pages:111710 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.intimp.2024.111710 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 130 |j 2024 |b 30 |c 03 |h 111710 | ||